the predictions, trained on patient samples, do not match the cell line validation results in scale, but they do match in direction and suggest a potential avenue by which drug combinations can be predicted/tested in other studies, which is prescient considering the number of current clinical trials targeting multiple AML targets, especially those using FLT3 inhibitors and venetoclax.61 The gene discussed is FLT3; the disease is acute myeloid leukemia.